 Shares of Chinook Therapeutics have reacted well recently to a surprising secondary offering conducted at 14.00, providing it with additional capital for the commercialization of atrasentan. Although only one likely inferior therapy has been approved for the companys initial target IgAN, plenty of potential competition looms. 